|
30 Sep 2025 |
Abbott
|
Consensus Share Price Target
|
29665.00 |
34487.25 |
- |
16.26 |
buy
|
|
|
|
|
21 May 2023
|
Abbott
|
ICICI Direct
|
29665.00
|
20315.00
|
20898.45
(41.95%)
|
|
Hold
|
|
|
|
|
13 Mar 2023
|
Abbott
|
Sharekhan
|
29665.00
|
25243.00
|
20329.00
(45.92%)
|
Target met |
Buy
|
|
|
|
|
15 Feb 2023
|
Abbott
|
Axis Direct
|
29665.00
|
23000.00
|
20399.30
(45.42%)
|
Target met |
Buy
|
|
|
Recommendation: BUY
|
|
13 Feb 2023
|
Abbott
|
ICICI Direct
|
29665.00
|
21025.00
|
20272.15
(46.33%)
|
Target met |
Hold
|
|
|
|
|
10 Feb 2023
|
Abbott
|
Sharekhan
|
29665.00
|
25243.00
|
20680.15
(43.45%)
|
Target met |
Buy
|
|
|
|
|
17 Nov 2022
|
Abbott
|
ICICI Direct
|
29665.00
|
21725.00
|
19493.95
(52.18%)
|
Target met |
Hold
|
|
|
|
|
15 Nov 2022
|
Abbott
|
ICICI Securities Limited
|
29665.00
|
20523.00
|
19651.45
(50.96%)
|
Target met |
Hold
|
|
|
Abbott India’s (Abbott) Q2FY23 performance beat our estimates on the profitability front while revenues were largely in-line.
|
|
16 Aug 2022
|
Abbott
|
ICICI Direct
|
29665.00
|
21140.00
|
19069.75
(55.56%)
|
Target met |
Hold
|
|
|
|
|
12 Aug 2022
|
Abbott
|
Axis Direct
|
29665.00
|
20800.00
|
18793.35
(57.85%)
|
Target met |
Buy
|
|
|
Abbott India's strategy of Beyond the Pill' comprising awareness, diagnosis, treatment and compliance for consumers is expected to deliver continued growth for the business. Therefore, we maintain a BUY rating on the stock with a Target Price of Rs 20,800/share.
|
|
11 Aug 2022
|
Abbott
|
ICICI Securities Limited
|
29665.00
|
19478.00
|
19604.20
(51.32%)
|
Target met |
Hold
|
|
|
Abbott India’s (AIL) Q1FY23 performance was below our estimate on the profitability front.
|